OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumo ...Middle East

CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant...

Read More Details
Finally We wish PressBee provided you with enough information of ( OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumo )

Also on site :

• Chipotle’s new CEO is bringing back a missing ingredient to hit the chain’s next goal—raising annual sales per store to $4 million
• Broncos sign TE Caden Prieskorn after injury hits the position
• I Tried 8 Store-Bought Mayos and the Winner Was Abundantly Clear